Mubadala and Qatar Investment Authority have joined a $575 million funding round in WHOOP, giving the Boston-based wearable health company a valuation of $10.1 billion and underscoring Gulf sovereign investors’ appetite for technology businesses tied to prevention, data and consumer health. The Series G round was led by Collaborative Fund and also drew backing from Abbott, Mayo Clinic and a group of high-profile athletes and public figures.
The investment places two of the Gulf’s most active state-backed investors behind a company that has tried to move beyond the crowded fitness-tracker market by positioning itself as a subscription-based health platform. WHOOP says it is focused on extending healthspan, improving performance and helping prevent disease before it develops, using continuous biometric monitoring and artificial intelligence models trained on more than 24 billion hours of physiological data.
For Mubadala and QIA, the deal fits a broader push into sectors seen as strategic for long-term diversification. Mubadala said in January that it was looking closely at artificial intelligence and robotics as major engines of future industrial growth, while QIA has been expanding its venture capital activities and in February said it would enlarge its venture programme to $3 billion as Doha works to deepen its technology ecosystem.
WHOOP’s appeal to investors rests partly on growth figures that suggest it has broken out of its niche among elite athletes. The company says it now has more than 2.5 million members worldwide, operated cash-flow positive in 2025 and ended that year with bookings up 103 per cent year on year, reaching a run rate of about $1.1 billion. It says the new capital will fund further expansion in the United States and abroad, including across Europe, the GCC, Latin America and Asia.
That international emphasis matters. Gulf sovereign investors have become increasingly visible in sectors that blend financial return with strategic influence, from artificial intelligence infrastructure to media, sport and consumer technology. Reuters reported in March that sovereign wealth funds across the region, which together oversee trillions of dollars, have kept diversification central to their investment plans even as geopolitical strains have sharpened. A fast-growing health technology platform with consumer reach and medical ambitions offers a way to tap another frontier of that strategy.
The company’s model also reflects a wider shift in digital health. IDC said global wearable device shipments rose 9.1 per cent in 2025 to 611.5 million units, suggesting demand remains solid even as the market matures. WHOOP has tried to distinguish itself from mass-market smartwatch makers through a screenless device, a membership model and heavier emphasis on sleep, recovery, strain and long-term health metrics.
Still, the investment is not without risk. WHOOP’s efforts to edge closer to medical-grade monitoring have drawn regulatory scrutiny in the United States. The Food and Drug Administration warned the company in July 2025 over its Blood Pressure Insights feature, saying the product had not been authorised for measuring or estimating a user’s blood pressure and that such functionality could place it within medical-device rules. WHOOP disputed that interpretation and argued the feature was intended for wellness rather than diagnosis. Reuters reported in January that the agency was considering a lighter touch for some health and fitness wearables, while still drawing a line around claims equivalent to blood pressure measurement.
That tension captures the central question hanging over companies like WHOOP: whether they can preserve the speed and appeal of consumer technology while moving deeper into healthcare, where evidence standards, compliance costs and liability risks are much higher. The presence of Abbott and Mayo Clinic in the funding round suggests investors see value in pushing the business toward more credible health applications, but it also raises expectations about what the platform should be able to prove.
The investment places two of the Gulf’s most active state-backed investors behind a company that has tried to move beyond the crowded fitness-tracker market by positioning itself as a subscription-based health platform. WHOOP says it is focused on extending healthspan, improving performance and helping prevent disease before it develops, using continuous biometric monitoring and artificial intelligence models trained on more than 24 billion hours of physiological data.
For Mubadala and QIA, the deal fits a broader push into sectors seen as strategic for long-term diversification. Mubadala said in January that it was looking closely at artificial intelligence and robotics as major engines of future industrial growth, while QIA has been expanding its venture capital activities and in February said it would enlarge its venture programme to $3 billion as Doha works to deepen its technology ecosystem.
WHOOP’s appeal to investors rests partly on growth figures that suggest it has broken out of its niche among elite athletes. The company says it now has more than 2.5 million members worldwide, operated cash-flow positive in 2025 and ended that year with bookings up 103 per cent year on year, reaching a run rate of about $1.1 billion. It says the new capital will fund further expansion in the United States and abroad, including across Europe, the GCC, Latin America and Asia.
That international emphasis matters. Gulf sovereign investors have become increasingly visible in sectors that blend financial return with strategic influence, from artificial intelligence infrastructure to media, sport and consumer technology. Reuters reported in March that sovereign wealth funds across the region, which together oversee trillions of dollars, have kept diversification central to their investment plans even as geopolitical strains have sharpened. A fast-growing health technology platform with consumer reach and medical ambitions offers a way to tap another frontier of that strategy.
The company’s model also reflects a wider shift in digital health. IDC said global wearable device shipments rose 9.1 per cent in 2025 to 611.5 million units, suggesting demand remains solid even as the market matures. WHOOP has tried to distinguish itself from mass-market smartwatch makers through a screenless device, a membership model and heavier emphasis on sleep, recovery, strain and long-term health metrics.
Still, the investment is not without risk. WHOOP’s efforts to edge closer to medical-grade monitoring have drawn regulatory scrutiny in the United States. The Food and Drug Administration warned the company in July 2025 over its Blood Pressure Insights feature, saying the product had not been authorised for measuring or estimating a user’s blood pressure and that such functionality could place it within medical-device rules. WHOOP disputed that interpretation and argued the feature was intended for wellness rather than diagnosis. Reuters reported in January that the agency was considering a lighter touch for some health and fitness wearables, while still drawing a line around claims equivalent to blood pressure measurement.
That tension captures the central question hanging over companies like WHOOP: whether they can preserve the speed and appeal of consumer technology while moving deeper into healthcare, where evidence standards, compliance costs and liability risks are much higher. The presence of Abbott and Mayo Clinic in the funding round suggests investors see value in pushing the business toward more credible health applications, but it also raises expectations about what the platform should be able to prove.
Topics
Gcc